

PEPPERPRINT

A NEW DIVERSITY




Uncovering antibody epitope signatures in COVID-19 patients by high-density peptide microarray screening

Dr. Kirsten Heiss
Research & Development
PEPperPRINT GmbH


June 2021

Globally > 170 million confirmed cases



- respiratory illness
- course of disease varies in symptoms and severity
- possible long-term effects (long COVID) in convalescents
- caused by a newly emerged coronavirus, SARS-CoV-2
- multiple SARS-CoV-2 variants are circulating globally

Understanding the host immune defense




Source: Funk CD et al., *Front Pharmacol.*, 2020

Essential for anti-viral defense:


- virus neutralization

Significance to understand humoral responses:

- strategies for active and passive immunization
- accurate serological diagnostics
- epidemiological studies




Proteome-wide antibody screening




Whole proteome of SARS-CoV-2 isolate Wuhan-Hu-1 (GenBank ID: MN908947.3) translated into 4,883 individual peptides

SARS-COV-2-naive




SARS-COV-2-infected



Epitope-resolved view of antibody responses

Our Platform Technology

- High spot density (1,200 peptides/cm²)
- Digital printing flexibility: multiple formats with high scalability
- Fast production times
- High peptide quality with routine double couplings
- Very low material consumption





SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients


Tatjana Schwarz^{1†}, Kirsten Heiss^{2†}, Yuvaraj Mahendran², Fiordiligie Casilag², Florian Kurth³, Leif E. Sander³, Clemens-Martin Wendtner⁴, Manuela A. Hoehstetter⁴, Marcel A. Müller¹, Renate Sekul², Christian Drosten^{1,5}, Volker Stadler^{2*†} and Victor M. Corman^{1,5*†}

OPEN ACCESS


Edited by:
Sean X. Leng,
Johns Hopkins University,
United States

¹ Institute of Virology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany, ² PEPPERPRINT GmbH, R&D unit, Heidelberg, Germany, ³ Department of Infectious Diseases and Respiratory Medicine, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany, ⁴ Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilians University (LMU), Munich, Germany, ⁵ German Centre for Infection Research, Associated Partner Charité, Berlin, Germany

SARS-CoV-2 proteome-wide antibody screening




SARS-CoV-2 proteome-wide antibody screening




Longevity of epitope-specific antibody responses


- Longitudinal antibody response to SARS-CoV-2 Spike S1



- Neutralization titers






Longevity of epitope-specific antibody responses




- Heterogeneous breadth of antibody responses across COVID-19 patients for both IgG and IgA
- IgG: increasing epitope-specific antibody responses in most instances towards later time points
- IgA: early responses rather weak; peak in antibody responses 3 weeks p.s.o. before declining for most of the epitopes

Longevity of epitope-specific antibody responses




IgG




Percent responders



IgA




Percent responders




$E_{6662}-R_{6676}$: a potential serological marker



- Most epitopes could be assigned to proteins located in the ORF1a/b polyprotein
- Significant reactivity against a NSP15-derived peptide ($E_{6662}-R_{6676}$) across the entire time span of analysis
- The other peptides were only significant at the late convalescent phase
- Spike protein-derived epitope $C_{649}-D_{663}$ is located in the S1 domain, adjacent to the S1/S2 cleavage site





SARS-CoV-2 proteome-wide antibody screening



Higher antibody response against S1 in severe COVID-19







Epitope signatures in mild & severe COVID-19



VSN normalized IgG reactivity
4 10

VSN normalized IgA reactivity
4 10

Epitope recognition associated with severe COVID-19




SARS-CoV-2 proteome-wide antibody screening identified:

- Antibody responses to linear B cell epitopes potentially applicable as serological markers of early and/or late SARS-CoV-2 infection
- Antibody responses to a Spike S1 epitope, which may interfere with furin-mediated cleavage
- Epitopes as potential biomarkers able to discriminate severe from mild COVID-19 disease courses
- Further validation of suitability as serological markers needed (e.g. larger patient cohorts)

SARS-CoV-2 customer studies



PEPPERPRINT
A NEW DIVERSITY



Vaccines and Antiviral Agents

SARS-CoV-2 spike protein stabilized in the closed state induces potent neutralizing responses.

George W. Carroll, Katarzyna A. Ciazynska, David A. Wells, Xiaoli Xiong, Ernest T. Aguinam, Stephen H. McLaughlin, Donna Mallery, Soraya Ebrahimi, Lourdes Ceron-Gutierrez, Benedikt Asbach, Sebastian Einhauser, Ralf Wagner, Leo C. James, Rainer Doffinger, Jonathan L. Heeney, John A. G. Briggs

DOI: 10.1128/JVI.01203-21

MRC Laboratory of Molecular Biology, anti-Spike responses



Article

Longitudinal Development of Antibody Responses in COVID-19 Patients of Different Severity with ELISA, Peptide, and Glycan Arrays: An Immunological Case Series

Jasmin Heidepriem^{1,†}, Christine Dahlke^{2,3,4,*}, Robin Kobbe², René Santer⁵, Till Koch^{2,3,4}, Anahita Fathi^{2,3,4}, Bruna M. S. Seco¹, My L. Ly^{2,3,4}, Stefan Schmiedel², Dorothee Schwinge⁶, Sonia Serna⁷, Katrin Sellrie¹, Niels-Christian Reichardt^{7,8}, Peter H. Seeberger¹, Marylyn M. Addo^{2,3,4,*}, Felix F. Loeffler^{1,*} and on behalf of the ID-UK COVID-19 Study Group[†]

MPI of Colloids and Interfaces, proteome-wide screening



Article

SARS-CoV-2 Epitope Mapping on Microarrays Highlights Strong Immune-Response to N Protein Region

Angelo Musicò^{1,†}, Roberto Frigerio^{1,†}, Alessandro Mussida¹, Luisa Barzon², Alessandro Sinigaglia², Silvia Riccetti², Federico Gobbi³, Chiara Piubelli³, Greta Bergamaschi¹, Marcella Chiari¹, Alessandro Gori^{1,*} and Marina Cretich^{1,*}

National Research Council of Italy, proteome-wide screening

Hindawi
Journal of Immunology Research
Volume 2020, Article ID 9465398, 8 pages
<https://doi.org/10.1155/2020/9465398>




Research Article

Generation of Chicken IgY against SARS-COV-2 Spike Protein and Epitope Mapping

Yan Lu¹, Yajun Wang², Zhen Zhang³, Jingliang Huang⁴, Meicun Yao⁵, Guobin Huang⁶, Yuanyuan Ge⁶, Peichun Zhang¹, Huaxin Huang¹, Yong Wang⁷, Huiliang Li² and Wen Wang¹

Huamin Medicine Co Ltd, anti-Spike responses

Applications for peptide microarrays





ARTICLE OPEN

Immunization with full-length *Plasmodium falciparum* merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial

Antje Blank^{1,9}, Kristin Fürle^{2,9}, Anja Jäschke^{3,9}, Gerd Mikus¹, Monika Lehmann³, Johannes Hüsing³, Kirsten Heiss⁴, Thomas Giese⁵, Darrick Carter⁶, Ernst Böhnlein⁷, Michael Lanzer^{2,10*}, Walter E. Haefeli^{1,10*} and Hermann Bujard^{7,8,10}

Heidelberg Hospital & Sumaya Biotech, Malaria Vaccine Phase 1 Trial

ARTICLE OPEN

Immunization of mice with chimeric antigens displaying selected epitopes confers protection against intestinal colonization and renal damage caused by Shiga toxin-producing *Escherichia coli*

David A. Montero^{1,2}, Felipe Del Canto¹, Juan C. Salazar¹, Sandra Céspedes¹, Leandro Cádiz¹, Mauricio Arenas-Salinas³, José Reyes⁴, Ángel Oñate⁵ and Roberto M. Vidal^{1,5}✉

Universidad de Chile, Epitope Screening for Antigen Design

RESEARCH ARTICLE

Epitopes of Naturally Acquired and Vaccine-Induced Anti-Ebola Virus Glycoprotein Antibodies in Single Amino Acid Resolution

Jasmin Heidepriem, Verena Krähling, Christine Dahlke, Timo Wolf, Florian Klein, Marilyn M. Addo,* Stephan Becker,* and Felix F. Loeffler*

BNI for Tropical Medicine, EBOV Antibody Signatures



ARTICLE

Received 23 Jun 2016 | Accepted 20 Oct 2016 | Published 14 Dec 2016

DOI: 10.1038/ncomms13627

OPEN

Functional screening for anti-CMV biologics identifies a broadly neutralizing epitope of an essential envelope protein

Thomas J. Gardner¹, Kathryn R. Stein¹, J. Andrew Duty^{1,2}, Toni M. Schwarz¹, Vanessa M. Noriega¹, Thomas Kraus², Thomas M. Moran^{1,2} & Domenico Tortorella¹

Icahn School of Medicine, Immunotherapeutics and Vaccines

Biomarker discovery & epitope mapping



Identification of three immunodominant motifs with atypical isotype profile scattered over the *Onchocerca volvulus* proteome

Ole Lagatie, Bieke Van Dorst, Lieven J. Stuyver

13
Save

4
Citation

1,992
View

1
Share

Janssen Diagnostics, Proteome-wide Epitope Mappings

Mapping Putative B-Cell Zika Virus NS1 Epitopes Provides Molecular Basis for Anti-NS1 Antibody Discrimination between Zika and Dengue Viruses

Marjorie C. L. C. Freire, Laécio Pol-Fachin, Danilo F. Coêlho, Isabelle F. T. Viana, Tereza Magalhães, Marli T. Cordeiro, Nico Fischer, Felix F. Loeffler, Thomas Jaenisch, Rafael F. Franca, Ernesto T. A. Marques, and Roberto D. Lins

Aggeu Magalhães Institute & Federal University of Pernambuco

Identification of a Zika NS2B epitope for which absence of IgG response is associated with severe neurological symptoms and the design of a biomarker capable of discriminatory diagnostics between severe and non-severe clinical phenotypes

Felix F. Loeffler, Isabelle F. T. Viana, Nico Fischer, Danilo F. Coêlho, Carolina S. Silva, Antônio F. Purificação Jr., Catarina M.C.S. Araújo, Bruno H.S. Leite, Ricardo Durães-Carvalho, Tereza Magalhães, Clarice N.L. Moraes, Marli T. Cordeiro, Roberto D. Lins, Ernesto T.A. Marques and Thomas Jaenisch

Heidelberg Hospital & Aggeu Magalhães Institute, Epitope mapping

Major antigen and paramyosin proteins as candidate biomarkers for serodiagnosis of canine infection by zoonotic *Onchocerca lupi*

Maria Stefania Latrofa, Giuseppe Palmisano, Glada Annoscia, Ciro Leonardo Piarri, Ramaswamy Chandrasekar, Domenico Otranto

0
Save

1
Citation

513
View


0
Share

University of Bari & Bu-Ali Sina University, Epitope mapping

Applications for peptide microarrays



ANTIBODY VALIDATION



INFECTIOUS DISEASES



BIOMARKER DISCOVERY



VACCINE DEVELOPMENT



AUTOIMMUNE RESEARCH



CANCER RESEARCH



TARGET BINDER



ALLERGY RESEARCH

PEPPERPRINT
A NEW DIVERSITY



Thank you for joining the webinar

Contact

Dr. Kirsten Heiss

Research & Development

PEPPERPRINT GmbH

Tullastrasse 2

69126 Heidelberg, Germany

Visit us: www.pepperprint.com

Get in touch: info@pepperprint.com

 [pepperprint-gmbh](https://www.linkedin.com/company/pepperprint-gmbh)

 [@pepperchip](https://twitter.com/pepperchip)

 [pepperprint.gmbh](https://www.facebook.com/pepperprint.gmbh)

Workflow for statistical analysis

